Compounds for improved viral transduction
The present invention provides methods and compositions for improving the efficacy of viral transduction of cells. More particularly, the present invention provides methods and materials useful for safely and reliably improving the efficiency of methods for transducing cells, such as human hematopoietic stem cells (HSC), with viruses and/or viral vectors. The compositions and methods are useful for therapeutic indications amenable to treatment with hematopoietic stem cell gene therapies.
1. A method for increasing the transduction efficiency of CD34 + hematopoietic stem and/or progenitor cells cultured with a lentivirus comprising:
culturing the CD34 + hematopoietic stem and/or progenitor cells and the lentivirus in a culture medium that comprises a compound that increases prostaglandin EP receptor signaling, wherein the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus during, or prior to, culture with the compound that increases prostaglandin EP receptor signaling, and wherein the transduction efficiency of CD34 + hematopoietic stem and/or progenitor cells cultured with the lentivirus is increased compared to the transduction efficiency of the CD34 + hematopoietic stem and/or progenitor cells cultured with the lentivirus in the absence of the compound that increases prostaglandin EP receptor signaling,
wherein the compound that increases prostaglandin EP receptor signaling is selected from the group consisting of: prostaglandin E 2 (PGE 2 ), 16,16-dimethyl PGE 2 and analogues thereof.
2. The method of claim 1 , wherein the CD34 + hematopoietic stem and/or progenitor cells are CD34 + hematopoietic stem cells.
3. The method of claim 1 , wherein the CD34 + hematopoietic stem and/or progenitor cells are CD34 + hematopoietic progenitor cells.
4. The method of claim 1 , wherein the CD34 + hematopoietic stem and/or progenitor cells are CD34 + hematopoietic stem and progenitor cells.
5. The method of claim 1 , wherein
a) at least 50% of the CD34 + hematopoietic stem or progenitor cells are transduced;
b) at least 75% of the CD34 + hematopoietic stem or progenitor cells are transduced; or
c) at least 90% of the CD34 + hematopoietic stem or progenitor cells are transduced.
6. The method of claim 1 , further comprising culturing the CD34 + hematopoietic stem and/or progenitor cells and lentivirus in the presence of a histone deacetylase (HDAC) inhibitor.
7. The method of claim 6 , wherein the HDAC inhibitor is selected from the group consisting of: Trichostatin A (TSA), valproic acid (VPA), sodium butyrate, suberoylanilide hydroxamic acid (SAHA), sodium phenylbutyrate, depsipeptide, trapoxin (TPX), cyclic hydroxamic acid-containing peptide 1 (CHAP1), MS-275, LBH589, and PXD-101.
8. The method of claim 1 , wherein the lentivirus is a Human immunodeficiency virus (HIV) virus.
9. The method of claim 1 , wherein the lentivirus is pseudotyped with a vesicular stomatitis virus G-protein (VSV-G) envelope protein.
10. The method of claim 1 , wherein the CD34 + hematopoietic stem and/or progenitor cells are transduced with the lentivirus in the presence of the compound that increases prostaglandin EP receptor signaling.
11. The method of claim 1 , wherein
a) the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus in the presence of the compound that increases prostaglandin EP receptor signaling for at least twenty-four hours;
b) the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus in the presence of the compound that increases prostaglandin EP receptor signaling during the first twenty-four hours of transduction; or
c) the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus in the presence of the compound that increases prostaglandin EP receptor signaling between the first twenty-four hours of transduction and forty-eight hours of transduction.
12. The method of claim 1 , wherein the lentivirus comprises a vector comprising:
a. a left (5′) lentiviral long terminal repeat (LTR);
b. an expression control sequence operably linked to a gene of interest; and
c. a right (3′) lentiviral LTR.
13. The method of claim 12 , wherein the lentivirus comprises a vector comprising:
a. a left (5′) HIV-1 LTR;
b. a Psi packaging sequence (Ψ+);
c. an HIV-1 central polypurine tract/DNA flap (cPPT/FLAP);
d. a rev response element (RRE);
e. A β-globin promoter and a β-globin locus control region (LCR) operably linked to a gene of interest; and
f. a right (3′) lentiviral LTR that comprises:
i) one or more insulator elements, or
ii) a rabbit β-globin polyA sequence (rβgpA).
14. The method of claim 13 , wherein the lentivirus is replication defective.
15. The method of claim 12 , wherein the lentivirus comprises a vector comprising:
a) a left (5′) HIV-1 LTR;
b) a Psi (Ψ) packaging signal;
c) a cPPT/FLAP;
d) an RRE;
e) a myeloproliferative sarcoma virus enhancer, negative control region deleted, d1587rev primer-binding site substituted (MND) promoter, operably linked to a polynucleotide encoding a human ATP-binding cassette, sub-family D, member 1 (ABCD1) polypeptide;
f) a right (3′) HIV-1 LTR; and
g) a rabbit β-globin polyadenylation sequence.
16. The method of claim 15 , wherein the lentivirus is replication defective.
17. The method of claim 12 , wherein the lentivirus is replication defective.
18. The method of claim 1 , wherein the lentivirus is replication defective.
19. A method for increasing the transduction efficiency of CD34 + hematopoietic stem and/or progenitor cells cultured with a lentivirus comprising: culturing the CD34 + hematopoietic stern and/or progenitor cells and the lentivirus in a culture medium that comprises PGE 2 , wherein the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus during, or prior to, culture with the PGE 2 , and wherein the transduction efficiency of CD34 + hematopoietic stem and/or progenitor cells cultured with the lentivirus is increased compared to the transduction efficiency of the CD34 + hematopoietic stem and/or progenitor cells cultured with the lentivirus in the absence of the PGE 2 .
20. The method of claim 19 , wherein the CD34 + hematopoietic stem and/or progenitor cells are CD34 + hematopoietic stem cells.
21. The method of claim 19 , wherein the CD34 + hematopoietic stem and/or progenitor cells are CD34 + hematopoietic progenitor cells.
22. The method of claim 19 , wherein the CD34 + hematopoietic stem and/or progenitor cells are CD34 + hematopoietic stem and progenitor cells.
23. The method of claim 19 , wherein at least 50% of the CD34 + hematopoietic stem and/or progenitor cells are transduced.
24. The method of claim 19 , wherein at least 75% of the CD34 + hematopoietic stem and/or progenitor cells are transduced.
25. The method of claim 19 , wherein at least 90% of the CD34 + hematopoietic stem and/or progenitor cells are transduced.
26. The method of claim 19 , wherein the lentivirus is a Human immunodeficiency virus (HIV) virus.
27. The method of claim 19 , wherein the lentivirus is pseudotyped with a vesicular stomatitis virus G-protein (VSV-G) envelope protein.
28. The method of claim 19 , wherein the CD34+ hematopoietic stem and/or progenitor cells are transduced with the lentivirus in the presence of the PGE 2 .
29. The method of claim 19 , wherein the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus in the presence of the PGE 2 for at least twenty-four hours.
30. The method of claim 19 , wherein the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus in the presence of the PGE 2 during the first twenty-four hours of transduction.
31. The method of claim 19 , wherein the CD34 30 hematopoietic stem and/or progenitor cells are cultured with the lentivirus in the presence of the PGE 2 between the first twenty-four hours of transduction and forty-eight hours of transduction.
32. The method of claim 19 , wherein the lentivirus comprises a vector comprising:
a. a left (5′) lentiviral long terminal repeat (LTR);
b. an expression control sequence operably linked to a gene of interest; and
c. a right (3′) lentiviral LTR.
33. The method of claim 32 , wherein the lentivirus comprises a vector comprising:
a. a left (5′) HIV-1 LTR;
b. a Psi packaging sequence (Ψ+);
c. an HIV-1 central polypurine tract/DNA flap (cPPT/FLAP);
d. a rev response element (RRE);
e. a β-globin promoter and a β-globin locus control region (LCR) operably linked to a gene of interest; and
f. a right (3′) lentiviral LTR that comprises:
j) one or more insulator elements, or
ii) a rabbit β-globin polyA sequence (rβgpA).
34. The method of claim 33 , wherein the lentivirus is replication defective.
35. The method of claim 32 , wherein the lentivirus comprises a vector comprising:
a) a left (5′) HIV-1 LTR;
b) a Psi (Ψ) packaging signal;
c) a cPPT/FLAP;
d) an RRE;
e) a myeloproliferative sarcoma virus enhancer, negative control region deleted, d1587rev primer-binding site substituted (MND) promoter, operably linked to a polynucleotide encoding a human ATP-binding cassette, sub-family D, member 1 (ABCD1) polypeptide;
f) a right (3′) HIV-1 LTR; and
g) a rabbit β-globin polyadenylation sequence.
36. The method of claim 35 , wherein the lentivirus is replication defective.
37. The method of claim 32 , wherein the lentivirus is replication defective.
38. A method for increasing the transduction efficiency of CD34 + hematopoietic stem and/or progenitor cells cultured with a lentivirus comprising: culturing the CD34 + hematopoietic stem and/or progenitor cells and the lentivirus in a culture medium that comprises 16,16-dimethyl PGE 2 , wherein the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus during, or prior to, culture with the 16,16-dimethyl PGE 2 , and wherein the transduction efficiency of CD34 + hematopoietic stem and/or progenitor cells cultured with the lentivirus is increased compared to the transduction efficiency of the CD34 + hematopoietic stem and/or progenitor cells cultured with the lentivirus in the absence of the 16,16-dimethyl PGE 2 .
39. The method of claim 38 , wherein the CD34 + hematopoietic stem and/or progenitor cells are CD34 + hematopoietic stem cells.
40. The method of claim 38 , wherein the CD34 + hematopoietic stem and/or progenitor cells are CD34 + hematopoietic progenitor cells.
41. The method of claim 38 , wherein the CD 34 + hematopoietic stem and/or progenitor cells are CD34 + hematopoietic stem and progenitor cells.
42. The method of claim 38 , wherein at least 50% of the CD34 + hematopoietic stem and/or progenitor cells are transduced.
43. The method of claim 38 , wherein at least 75% of the CD34 + hematopoietic stem and/or progenitor cells are transduced.
44. The method of claim 38 , wherein at least 90% of the CD34 + hematopoietic stem and/or progenitor cells are transduced.
45. The method of claim 38 , wherein the lentivirus is a Human immunodeficiency virus (HIV) virus.
46. The method of claim 38 , wherein the lentivirus is pseudotyped with a vesicular stomatitis virus G-protein (VSV-G) envelope protein.
47. The method of claim 38 , wherein the CD34 + hematopoietic stem and/or progenitor cells are transduced with the lentivirus in the presence of the 16,16-dimethyl PGE 2 .
48. The method of claim 38 , wherein the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus in the presence of the 16,16-dimethyl PGE 2 for at least twenty-four hours.
49. The method of claim 38 , wherein the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus in the presence of the 16,16-dimethyl PGE 2 during the first twenty-four hours of transduction.
50. The method of claim 38 , wherein the CD34 + hematopoietic stem and/or progenitor cells are cultured with the lentivirus in the presence of the 16,16-dimethyl PGE 2 between the first twenty-four hours of transduction and forty-eight hours of transduction.
51. The method of claim 38 , wherein the lentivirus comprises a vector comprising:
a. a left (5′) lentiviral long terminal repeat (LTR);
b. an expression control sequence operably linked to a gene of interest; and
c. a right (3′) lentiviral LTR.
52. The method of claim 51 , wherein the lentivirus comprises a vector comprising:
a. a left (5′) HIV-1 LTR;
b. a Psi packaging sequence (Ψ+);
c. an HIV-1 central polypurine tract/DNA flap (cPPT/FLAP);
d. a rev response element (RRE);
e. a β-globin promoter and a β-globin locus control region (LCR) operably linked to a gene of interest; and
f. a right (3′) lentiviral LTR that comprises:
k) one or more insulator elements, or
ii) a rabbit β-globin polyA sequence (rβgpA).
53. The method of claim 52 , wherein the lentivirus is replication defective.
54. The method of claim 51 , wherein the lentivirus comprises a vector comprising:
a) a left (5′) HIV-1 LTR;
b) a Psi (Ψ) packaging signal;
c) a cPPT/FLAP;
d) an RRE;
e) a myeloproliferative sarcoma virus enhancer, negative control region deleted, d1587rev primer-binding site substituted (MND) promoter, operably linked to a polynucleotide encoding a human ATP-binding cassette, sub-family D, member 1 (ABCD1) polypeptide;
a right (3′) HIV-1 LTR; and
g) a rabbit β-globin polyadenylation sequence.
55. The method of claim 54 , wherein the lentivirus is replication defective.
56. The method of claim 51 , wherein the lentivirus is replication defective.